Early View e202503749
Research Article

Atorvastatin-Loaded Mineralized Vaccine Reprograms Endosomal Trafficking to Amplify STING-Driven Cancer Immunotherapy

Yuhan Yang

Yuhan Yang

Department of Pharmaceutics, School of Pharmacy, Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, 211198 P.R. China

Both authors contributed equally to this work.

Search for more papers by this author
Wei Long

Wei Long

Department of Pharmaceutics, School of Pharmacy, Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, 211198 P.R. China

Both authors contributed equally to this work.

Search for more papers by this author
Xiangyu Pei

Xiangyu Pei

Department of Pharmaceutics, School of Pharmacy, Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, 211198 P.R. China

Search for more papers by this author
Shangfei Li

Shangfei Li

Department of Pharmaceutics, School of Pharmacy, Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, 211198 P.R. China

Search for more papers by this author
Bowen Fu

Bowen Fu

Department of Pharmaceutics, School of Pharmacy, Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, 211198 P.R. China

Search for more papers by this author
Hao Zhai

Hao Zhai

Department of Pharmaceutics, School of Pharmacy, Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, 211198 P.R. China

Search for more papers by this author
Xiaoyi Zhang

Xiaoyi Zhang

Department of Pharmaceutics, School of Pharmacy, Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, 211198 P.R. China

Search for more papers by this author
Ying Wan

Ying Wan

Department of Pharmaceutics, School of Pharmacy, Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, 211198 P.R. China

Search for more papers by this author
Prof. Yayun Peng

Corresponding Author

Prof. Yayun Peng

Department of Pharmaceutics, School of Pharmacy, Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, 211198 P.R. China

E-mail: [email protected]; [email protected]

Search for more papers by this author
Ting Cai

Corresponding Author

Ting Cai

Department of Pharmaceutics, School of Pharmacy, Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, 211198 P.R. China

E-mail: [email protected]; [email protected]

Search for more papers by this author
First published: 23 July 2025

Graphical Abstract

A biomineralized nanovaccine (OVA-ATV@MnO₂) spatiotemporally co-delivers and releases tumor antigen, atorvastatin, and Mn adjuvants in dendritic cells. Atorvastatin reprograms endosomal trafficking to delay lysosomal degradation, enhancing antigen cross-presentation via MHC-I, while Mn2+ activates the cGAS-STING pathway, amplifying dendritic cell maturation and antitumor T-cell responses. This dual-action strategy achieves potent tumor regression, suppresses metastasis, and establishes durable anticancer immunity.

Abstract

Dendritic cell (DC)-targeted nanovaccines offer great promise for cancer immunotherapy but are severely limited by premature lysosomal degradation of antigens, which reduces cross-presentation efficacy. Here, we report a facile yet effective biomineralization strategy to construct nanovaccine (OVA-ATV@MnO₂) that co-delivers ovalbumin (OVA) and atorvastatin (ATV) within MnO₂ matrix. The ATV-mediated nanovaccine reprograms endosomal trafficking by inhibiting the mevalonate (MVA) pathway, thereby delaying endosomal maturation and preventing antigen diversion to degradative lysosomes. This intervention significantly enhances antigen preservation and MHC-I presentation in DCs. Simultaneously, the MnO₂ framework not only stabilizes the vaccine nanostructure but also releases Mn2⁺ ions as an adjuvant to potently activate the cGAS-STING pathway, amplifying DC maturation and antitumor T-cell priming. In vivo studies demonstrate that the nanovaccine induces robust tumor regression, suppresses metastasis, and establishes durable prophylactic immunity. By synergistically rewiring intracellular antigen trafficking and amplifying STING-mediated immune activation, this mineralized vaccine platform provides a transformative strategy for precise cancer immunotherapy.

Conflict of Interests

The authors declare no conflict of interest.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.